An updated panel of 578 barcoded cancer cell lines were used to profile the activity of 4518 existing drugs with a diversity of indications. An unexpectedly large number of non-oncology drugs selectively inhibited subsets of cancer cell lines. Results were used to begin the PRISM drug repurposing resource (depmap.org/repurposing).
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling